ACTOBIOTICS®: MICROBE-BASED PHARMACEUTICAL AGENTS

for expression and local delivery of therapeutics at disease sites

including the intestine, the mouth and the nasopharynx.

NEWS

Our partner, Oragenics, Inc., has announced completion of enrollment of its Phase 2 clinical trial for AG013 in oral mucositis

PRODUCTS

ActoBio Therapeutics™ has a rich pipeline of therapeutic agents, called ActoBiotics®, that are developed to treat a number of diseases, focusing primarily on disease areas with high unmet needs in immunotherapy, allergy and immune tolerance induction.

PLATFORM

ActoBiotics® are based on the well-characterized, safe food-grade bacterium Lactococcus lactis. They are specifically designed and engineered to perform very specific biological interventions across broad therapeutic applications.

clinical and
developmental
pipeline